Initial experiences with infliximab at the National Medical Center, Hungary

Introduction: Infliximab (Remicade) is a new therapeutic option for chronic, refractory or fistulizing Crohn's disease. Here we report our initial experiences. Methods: Between November of 2002 and February of 2004, 17 patients were treated with infliximab at our department. The ages of the 5 women and 12 men were between 25 and 59 years (mean age was 38, 8 years). The patients received 5mg/kg of the drug in intravenous drips. Nine of them received the infusion 3 times according to the recommended protocols, on week 0, 2 and 6 week, in two cases the treatment was aborted after the second infusion due to serious…